Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.06.19
Views: 1950

Dr Tira Tan - National Cancer Centre, Singapore

Dr Tira Tan speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the phase II DORA study.

She explains that the trial uses the PARP inhibitor olaparib alone or in combination with the PD-L1 inhibitor durvalumab to treat patients with platinum responsive advanced triple-negative breast cancer, thereby using a maintenance strategy to reduce the toxicities experienced by patients.

Dr Tan says that they are expecting some correlative work to come out of this study that will inform them on which patient populations may benefit most from this approach. She also provides her insights on the potential of PARP inhibitors in other settings.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation